The purpose of this trial is to test if treatment with the trial drug, tralokinumab, can
affect the body's immune response to vaccines. The trial will also evaluate the efficacy of
tralokinumab when it is given concomitantly with vaccines.> The trial includes a screening
period of 2 to 6 weeks, a treatment period of 16 weeks (Weeks 0 to 16), and a 14-week
off-treatment follow-up period for the assessment of safety (Weeks 16 to 30). Eligible
subjects may transfer to an open-label, long-term trial at Week 16 or later.